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ABSTRACT
Meningioma 1 (MN1) gene overexpression has been reported in acute myeloid 
leukaemia (AML) patients and identified as a negative prognostic factor. In order to 
characterize patients presenting gene overexpression and to verify if MN1 transcript 
could be a useful marker for minimal residual disease detection, MN1 was quantified 
in 136 AML patients with different cytogenetic risk and in 50 normal controls. In 
20 patients bearing a fusion gene transcript suitable for minimal residual disease 
quantitative assessment and in 8 patients with NPM1 mutation, we performed a 
simultaneous analysis of MN1 and the fusion-gene transcript or NPM1 mutation during 
follow-up. Sequential MN1 and WT1 analysis was also performed in 13 AML patients 
lacking other molecular markers. The data obtained show that normal cells consistently 
express low levels of MN1 transcript. In contrast, high levels of MN1 expression are 
present in 47% of patients with normal karyotype and in all cases with inv(16). MN1 
levels during follow-up were found to follow the pattern of other molecular markers 
(fusion gene transcripts, NPM1 and WT1). Increased MN1 expression in the BM during 
follow up was always found to be predictive of an impending hematological relapse.
INTRODUCTION
The assessment of minimal residual disease (MRD) 
has currently become a necessary strategy to better 
address treatment intensity in acute leukemias [1]. The 
detection of MRD by RT-PCR is limited to those patients 
characterized by genetic markers. The latter include fusion 
genes derived from chromosome translocations, such as 
PML-RARα AML1 and CBF-MYH112 or mutations, for 
example nucleophosmin (NPM1), [1, 3] which has been 
validated as a sensitive marker of MRD detection. More 
recently, studies of next generation sequencing (NGS) 
allowed to enlarge the spectrum of genetic abnormalities 
by discovering new mutations and aberrations [4] 
Basing on these studies, other genetic markers are under 
investigation, including IDH1 and IDH2 mutations which 
occur in less than 10% of the patients[5].
Other genes found overexpressed in AML have been 
validated for MRD detection in many clinical settings. 
Among them, one of the most exploited is the Wilms 
tumor gene ( WT1) [6–8].
Studies of NGS clearly showed that in AML at 
diagnosis there is a founding clone which prevails and 
several small subclones, characterized by different mutations, 
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which are often undetectable by Sanger sequencing. These 
subclones can be selected by chemotherapy or by molecular 
targeted therapies and expand over time thus generating 
chemoresistance or relapse [4, 9].
Many studies suggest that WT1, although not 
associated with a specific leukemic clone, is very sensitive 
in the detection of the persistence or of the reappearance 
of the disease [8] The fact that its expression is not related 
to specific genetic alterations allows WT1 to monitor 
the kinetic of the leukemic cells. Since WT1 is not 
overexpressed only in AML but in other hematological 
malignancies including myelodysplastic syndromes 
[10] and myeloproliferative disorders, [11] it could be 
considered a “universal marker” of clonal hematopoiesis. 
Despite the fact that the majority of AML at diagnosis 
overexpresses WT1, in about 20-30% of AML the gene is 
not significantly overexpressed [8]. We therefore explored 
the possibility of additional molecular markers to monitor 
the disease.
The meningioma 1 gene (MN1), located on 
chromosome 22q11, was cloned from a patient affected 
by meningioma characterized by the translocation 
t(4;22) (p16;q11) [12]. Additional studies identified the 
fusion between TEL and MN1 genes in AML patients 
with translocations t(12;22) (p13;q11) [13]. This genetic 
alteration, although very rare, represents a relevant 
prognostic factor with a negative impact on survival. 
Despite the role of this fusion transcript, it was shown 
that MN1 overexpression represents a negative prognostic 
factor in terms of disease free survival [14].
Heuser and colleagues [14] investigated the 
significance of MN1 expression in a uniformly treated 
cohort of adult AML patients with normal karyotype. In 
this study the prognostic relevance of MN1 was compared 
to other prognostic factors such as FLT3 internal tandem 
duplication (ITD), MLL and NPM1 mutations. This study 
suggests that MN1 overexpression is an independent 
prognostic marker in AML with normal karyotype and it 
is associated with shorter relapse free survival (RFS) and 
shorter overall survival (OS) [14].
The two main objects of the present study were the 
identification and characterization of the subset of patients 
showing MN1 overexpression and the validation of MN1 
as a marker for MRD detection.
RESULTS
MN1 expression in AML patients at diagnosis
The expression levels of MN1 transcript in normal 
controls and in leukemia samples at diagnosis are 
summarized in Table 1, 2 and Figure 1. The MN1 levels 
were very low in normal samples: the mean copy number 
of MN1/104 ABL copies is 130±94 (median 136; range 
9-300) in peripheral blood (PB) and 285 ±117 in BM 
(median 254, range 80-500).
Similarly, low levels of expression were detected 
in normal CD34+ cells obtained from healthy volunteers: 
mean MN1 copies/104 ABL copies 223±56 (median 215 
copies/104 ABL copies, range 149-300).
Conversely, as shown in Table 1 and 2, 47% of 
the samples collected at diagnosis from AML patients 
characterized by a normal karyotype showed abnormal 
expression of the MN1 gene. In this subset of patients, 
the mean value of expression evaluated for 37 out of 79 
BM samples showed a transcript amount above the upper 
limit of normal controls is 9707±16590 copies/104 ABL 
copies (median 5136, range 852-90230). Interestingly, 
as shown in Figure 1, NK AML and CBF AML seem to 
segregate in two groups, one with normal values (below 
500 MN1 copies/104 ABL copies for BM and 300 MN1 
copies for PB), the second with MN1 values above 1000 
copies. This raises the possibility of a “gray zone” between 
positivity and negativity. At present we cannot establish 
the prognostic significance of MN1 with values falling in 
that range.
In accordance, 9 out of 19 PB samples presented 
abnormal expression with a mean value of 7125± 4663 
(median 6780, range 1367-15900). All samples carrying 
the fusion transcript CBβ-MYH11 expressed a significantly 
higher amount of MN1 transcript. The mean copy number 
is 44270±26285 (median 46950, range 2149-98000) in 
BM and 35200±21771 (median 34500, range 1400-67999) 
in PB. These values are significantly higher as compared 
to controls (p<0.0001 in both BM and PB). Fifty % of 
the samples characterized by the fusion gene RUNX1-
AML1 abnormally expressed MN1. The mean value of 
MN1 copies calculated for BM cells with MN1 expression 
above the upper limit established by normal samples was 
17848±10925 (median 16950, range 3500-34000). All 
four PB samples tested presented high MN1 values with 
a mean copy number of 16052±26665 (median 3475, 
range 1260-56000). Additionally, four AML patients with 
sporadic abnormalities such a t(9;22), trisomy 9, 5q-, and 
complex karyotype were included. All expressed abnormal 
MN1 transcript values (data shown in Table 1). Finally, 
the Acute Promyelocytic Leukaemia (APL) samples 
expressed MN1 values comparable to those of healthy 
subjects in both BM (p= 0.4) and PB (p=0.08).
Interestingly, the paired analysis of 47 PB and 
BM samples collected from the same cohort of patients 
allowed us to establish a remarkable correlation between 
MN1 expression in PB and BM. Regression analysis 
provided an r value of 0.91 (Figure 2).
Stratification of patients according to the presence 
of FLT3 mutation or internal tandem duplication (ITD) 
demonstrated no significant association between the two 
abnormalities. MN1 was overexpressed in 35% of patients 
with FLT3 ITD, 33% of patients with the D835 mutation 
and 50% of those with wild type FTL3.
Finally, in contrast to previously published data, we 
were unable to find any significant correlation between 
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Table 1: MN1 expression in normal and AML samples. BM= bone marrow, PB= peripheral blood NV= not valuable, 
SD= standard deviation, CTRL= healthy control
Cytogenetic 
group
Type of 
samples
No. of samples 
tested
No. and 
percentage 
of patients 
with MN1 
overexpression
MN1 copies/104ABL copies
Mean value ± SD Median value range
CTRL BM 20 285±117 254 80-500
PB 30 130±94 136 9-300
CD34+ 6 223±56 215 149-300
TOTAL 56
AML normal karyotype BM 79 37 (47%) 9766±16590 5136 852-90230
PB 19 9 (47%) 7125±4663 6780 1367-15900
t(15;17) BM 25 0 (0%) 129±49 130 25-219
PB 7 0 (0%) 99±75 95 20-250
inv(16) BM 16 16 (100%) 44270±26285 46950 2149-98000
PB 6 6 (100%) 35200±21771 34500 1400-67999
t(8;21) BM 12 6 (50%) 17848±10925 16950 3500-34000
PB 4 4 (100%) 16052±26665 3475 1260-56000
complex K BM 1 1 (100%) 21080 NV NV
t(9;22) BM 1 1(100%) 9860 NV NV
trysomy 9 BM 1 1(100%) 8770 NV NV
5q- BM 1 1(100%) 45935 NV NV
TOTAL 172
Table 2: Clinical characteristics of the patients enrolled in the study. Treatment, indicated as A, B, C and D, is 
described in the “materials and methods” section
UPN age sex cytogenetic NPM1 FLT3 treatment
MN1 
copies/10000
ABL copies 
in BM
WT1 
copies/10000
ABL copies 
in BM
NPM1 
copies/10000 
ABL copies
1 22 M NK y N A 199 156 10230
2 36 M NK y Y A 15900 3688 1860
3 66 F NK y Y B 199 270 6780
4 70 M NK y N B 111 189 7620
5 38 F NK y N A 145 340 NA
6 44 F NK y N A 199 1560 11831
7 49 F NK y N A 111 223 4210
8 57 F NK y N A 322 1700 NA
9 72 M NK y N B 444 568 NA
(Continued )
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UPN age sex cytogenetic NPM1 FLT3 treatment
MN1 
copies/10000
ABL copies 
in BM
WT1 
copies/10000
ABL copies 
in BM
NPM1 
copies/10000 
ABL copies
10 61 M NK y Y C 430 13400 3280
11 19 F NK y N A 90230 13200 8800
12 28 M NK y N A 10240 3400 NA
13 32 M NK y Y A 50 450 12555
14 45 M NK y N A 3570 22 NA
15 31 M NK y Y A 56000 3240 18340
16 60 F NK y N A 11100 390 2102
17 66 M NK y Y B 14637 12 NA
18 73 F NK y N B 265 590 NA
19 74 F NK y N B 300 200 9090
20 29 F NK y N A 1453 37 15910
21 18 M NK y Y A 111 11 NA
22 26 M NK y N A 2450 2350 2230
23 29 F NK y N A 4500 8090 NA
24 38 F NK y N A 5080 9030 NA
25 54 M NK y N A 344 88 13905
26 58 M NK y N A 1460 9000 NA
27 73 M NK y N B 2466 45 17600
28 70 F NK y N B 8799 23 NA
29 48 F NK y N A 666 1900 NA
30 68 F NK y Y B 156 340 1190
31 44 M NK y N A 468 1200 NA
32 41 M NK y N A 2566 18 220
33 50 F NK y N A 243 2510 NA
34 74 M NK y N B 222 2560 NA
35 73 F NK y N B 1890 40 80279
36 30 M NK y N A 1570 62 NA
37 49 F NK y N A 5555 5200 NA
38 45 M NK y N A 400 250 7700
39 27 M NK y Y A 345 660 NA
40 69 F NK y N B 6870 66 NA
41 22 F NK y N A 1790 21900 2200
42 30 M NK y N A 5666 10300 NA
43 68 M NK y N B 3573 10 NA
44 65 M NK y N B 1888 23200 14200
45 61 F NK y N A 12500 8700 NA
(Continued )
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UPN age sex cytogenetic NPM1 FLT3 treatment
MN1 
copies/10000
ABL copies 
in BM
WT1 
copies/10000
ABL copies 
in BM
NPM1 
copies/10000 
ABL copies
46 45 M NK N N A 120 7800
47 31 M NK N N A 258 2140
48 30 F NK N Y A 340 220
49 48 F NK N N A 422 900
50 44 F NK N N A 254 8560
51 48 F NK N N C 18890 22
52 31 F NK N D835 A 299 334
53 64 M NK N N A 154 14500
54 63 M NK N N C 197 2230
55 20 F NK N N A 15730 13200
56 46 M NK N N A 13000 78
57 66 F NK N N B 312 223
58 33 M NK N Y A 311 1880
59 47 M NK N N A 4500 34
60 74 F NK N N B 500 890
61 60 F NK N N C 211 228
62 61 M NK N N A 466 2460
63 70 M NK N N B 444 2184
64 22 M NK N N A 499 3340
65 50 M NK N N A 476 5510
66 49 F NK N N C 311 1990
67 32 F NK N N A 6780 28
68 72 F NK N N B 8900 88
69 44 F NK N N A 222 750
70 70 M NK N D835 B 143 145
71 28 M NK N N A 5136 2200
72 36 F NK N N A 5305 5780
73 49 M NK N N A 852 31
74 51 F NK N N A 1674 8800
75 70 M NK N N B 1367 3280
76 66 M NK N D835 B 1790 1120
77 42 F NK N Y A 200 676
78 26 F NK N N A 210 2250
79 19 F NK N N A 5680 34
80 56 F t(15;17) N N D 192 13450
(Continued )
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UPN age sex cytogenetic NPM1 FLT3 treatment
MN1 
copies/10000
ABL copies 
in BM
WT1 
copies/10000
ABL copies 
in BM
NPM1 
copies/10000 
ABL copies
81 66 F t(15;17) N N D 165 23410
82 34 M t(15;17) N N D 177 7850
83 51 M t(15;17) N N D 219 8400
84 58 M t(15;17) N N D 200 29800
85 38 M t(15;17) N N D 166 78400
86 44 F t(15;17) N Y D 130 17320
87 50 M t(15;17) N N D 167 54700
88 39 F t(15;17) N N D 155 3300
89 51 F t(15;17) N N D 150 7120
90 49 M t(15;17) N N D 90 2650
91 48 M t(15;17) N Y D 25 11070
92 44 F t(15;17) N N D 122 62190
93 55 F t(15;17) N N D 160 9240
94 60 F t(15;17) N N D 150 8840
95 44 M t(15;17) N N D 140 3780
96 49 F t(15;17) N N D 113 14200
97 52 M t(15;17) N N D 80 5891
98 56 F t(15;17) N N D 69 830
99 41 F t(15;17) N N D 47 41690
100 65 M t(15;17) N N D 76 27260
101 59 M t(15;17) N N D 98 16980
102 55 M t(15;17) N Y D 89 27120
103 45 M t(15;17) N N D 100 20050
104 62 F t(15;17) N N D 120 15380
105 49 F t(8;21) N N A 34000 2180 12500
106 21 F t(8;21) N N A 3500 1650 6580
107 68 F t(8;21) N N B 9900 880 2490
108 35 M t(8;21) N N A 18000 1530 57810
109 51 M t(8;21) N N A 25788 14300 2250
110 66 F t(8;21) N N B 15900 4300 1570
111 32 M t(8;21) N N A 400 910 22500
112 56 F t(8;21) N N A 340 22800 4780
113 41 M t(8;21) N Y A 290 18300 7630
114 34 M t(8;21) N N A 350 5600 10300
115 48 M t(8;21) N N A 280 3490 8700
116 68 F t(8;21) N N B 380 19200 22800
(Continued )
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EVI-1 and MN1 expression (r= 0.06) or between MN1 and 
NPM1 mutation (r=0.2).
MN1 as a target for MRD detection
To assess the significance of MN1 expression as a 
marker for MRD detection in AML, the MN1 transcript 
amount was quantified during follow-up in 20 AML 
patients characterized by the presence of specific fusion-
gene transcripts (15 CBFβ-MYH11 and 5 RUNX1-AML1), 
in 8 patients with NPM1 mutation and in and 13 AML 
patients (including 3 resistant cases) lacking additional 
molecular markers but monitored by making use of 
WT1 quantitative assessment, which we have previously 
demonstrated to strictly parallel fusion gene transcript 
behavior [6]. In all cases characterized by the presence 
of a fusion-gene transcript, the longitudinal pattern of 
MN1 expression was always found to parallel that of the 
fusion gene. (Table 3) Three representative AML cases are 
illustrated in Figure 3. In the inv(16) AML subgroup, the 
patient who remained in continuous complete remission 
(CCR) constantly showed MN1 values within the normal 
range (Table 3), whereas the five patients who ultimately 
relapsed showed a progressive raising of MN1 levels 
above the normal range during hematological remission 
(Table 3 and Figure 3). In the cases illustrated in Figure 3 
panel A and C, MN1 values were found above the normal 
range in concomitance with quite stable values of CBFβ-
MYH11 transcript in BM samples taken 3 and 4 months, 
respectively, before hematological relapse while the 
patients were still in hematological remission.
Similarly, in the t(8;21) group, three patients who 
were in CCR never showed levels of MN1 transcript above 
the normal range (Table 3), whereas in the two patients 
who relapsed, increased MN1 levels were detectable 1 and 
2 months respectively before the evidence of relapse.
In addition in 8 patients with NPM1 mutation 
the quantitative analysis of MN1 and NPM1 shows a 
concordance between the two markers with a progressive 
increase of both before relapse and normal values of MN1 
and negative NPM1 during remission.
Finally, all patients were also monitored using 
WT1 quantitative assessment. As shown in Figure 3 
panel C, and as already demonstrated in our previous 
UPN age sex cytogenetic NPM1 FLT3 treatment
MN1 
copies/10000
ABL copies 
in BM
WT1 
copies/10000
ABL copies 
in BM
NPM1 
copies/10000 
ABL copies
117 29 F inv(16) N N A 21935 750 21192
118 59 M inv(16) N N A 24128 3190 9027
119 41 F inv(16) N N A 72022 1840 13580
120 42 F inv(16) N N A 98000 2600 8920
121 49 F inv(16) N N A 50900 2530 6510
122 22 M inv(16) N N A 59000 4160 62800
123 46 F inv(16) N N A 70280 3140 11519
124 51 M inv(16) N N A 68900 1020 37911
125 69 M inv(16) N N B 28000 1010 80134
126 39 M inv(16) N N A 45000 47620 10100
127 29 F inv(16) N N A 27900 5610 10180
128 60 F inv(16) N N A 4700 5990 12816
129 66 F inv(16) N N B 29804 6230 11280
130 61 M inv(16) N N A 56700 980 29880
131 46 F inv(16) N N A 48900 4700 10065
132 48 M inv(16) N N A 2149 390 NA
133 30 F complex K N N C 21080 36880
134 47 M t(9;22) N N A 9860 21370
135 60 M 46XY;+9 N N C 8770 28600
136 21 F 46XX;-5q N N A 45935 990
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study and in many studies from the literature, [15] WT1 
strictly paralleled the behaviour of the fusion transcripts. 
Furthermore, we found that MN1 strictly paralleled WT1 in 
patients without any fusion gene (Figure 4) and in patients 
with rearrangements in the core binding factor (Figure 
3C). Figure 4 shows the two molecular markers used 
during follow up of a patient who obtained a remission 
after two courses of chemotherapy and allogeneic bone 
marrow transplant. In this patient, both markers, WT1 and 
MN1, returned to normal range and both increased three 
months before relapse.
Although the presented examples show a good 
degree of concordance in the curves representing MN1 
and fusion genes, they are not completely parallel. In 
Figure 1: MN1 expression in PB (red dots) and BM (black dots) in samples from healthy volunteers, AML patients 
with normal karyotype, APL with t(15;17), AML with inv(16) and AML with t(8;21) chromosomal abnormalities. The 
transcript amount is expressed as MN1 copies/104 ABL copies.
Figure 2: Correlation between MN1 expression in PB and BM. The transcript amount is expressed as MN1 copies/104 ABL copies.
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Table 3: Simultaneous evaluation of the expression of MN1 and fusion gene transcript (CBF-MYH11 or RUNX1-
AML1) or NMP1 mutation during follow up in patients with AML
pt Target gene Diagnosis Post Induction
CR Post 
consolidation I
CR pst Post 
consolidation II follow-up Relapse
1 MN1 21935 210 190 192
CBF-MYH11 21192 167 12 12
2 MN1 24128 87 90 100
CBF-MYH11 9027 18 9 11
3 MN1 72022 312 290 97
CBF-MYH11 13580 212 21 8
4 MN1 98000 95 88 90
CBF-MYH11 8920 15 21 12
5 MN1 50900 320 190 261 190
CBF-MYH11 6510 134 67 52 30
6 MN1 59000 110 80 90
CBF-MYH11 62800 180 200 80
7 MN1 70280 88 113 180 883 3714
CBF-MYH11 11519 340 391 120 312 19711
8 MN1 68900 37 41 22
CBF-MYH11 37911 412 91 11
9 MN1 28000 512 193 114 121
CBF-MYH11 80134 670 120 69 21
10 MN1 45000 820 632 880 920 53490
CBF-MYH11 10100 8 4 1 3 9980
11 MN1 27900 91 102 100 920 10142
CBF-MYH11 10180 8 6 1 5 10090
12 MN1 4700 66 61 45
CBF-MYH11 12816 34 12 4
13 MN1 29804 97 112 118 121 32560
CBF-MYH11 11280 8 4 1 4 10120
14 MN1 56700 180 134 153
CBF-MYH11 29880 12 15 12
15 MN1 48900 812 410 880 970 10103
CBF-MYH11 10065 8 6 1 3 10012
pt Target gene Diagnosis Post Induction
CR Post 
consolidation I
CR pst Post 
consolidation II
follow-
up Relapse
16 MN1 34000 211 170 145 161
RUNX1-AML1 97170 4720 266 27 64
17 MN1 3500 118 111 131 880 18670
(Continued )
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some cases it seems that MN1 expression, similarly to 
WT1, is cleared more rapidly than fusion gene transcripts 
during induction of remission, but it also seems that its 
elevation is more indicative than the fusion gene transcript 
in predicting relapse (see Figure 3 panel A and C). At the 
moment this cannot be easily explained due to our lack of 
knowledge about the kinetics of MN1 expression in AML.
DISCUSSION
The negative impact of the persistence of minimal 
residual disease after chemotherapy or before bone 
marrow transplantation in acute myeloid leukemia 
patients is well established [1]. RT-PCR is among the 
most sensitive methods used for the quantification of the 
pt Target gene Diagnosis Post Induction
CR Post 
consolidation I
CR pst Post 
consolidation II
follow-
up Relapse
RUNX1-AML1 9027 19 7 5 12 8650
18 MN1 9900 407 112 109
RUNX1-AML1 11830 229 15 2
19 MN1 18000 110 141 390 1020 28910
RUNX1-AML1 9902 51 4 3 13 12500
20 MN1 25788 99 81 17
RUNX1-AML1 2250 22 12 8
pt Target gene Diagnosis Post Induction
CR Post 
consolidation I
CR pst Post 
consolidation II
follow-
up Relapse
21 MN1 15900 113 103 190 1020 24500
NPM1 1860 21 11 6 54 2830
22 MN1 90230 90 81 52
NPM1 8800 21 2 1
23 MN1 56000 2200 860 920 4290 82104
NPM1 18340 25 28 31 72 11454
24 MN1 1453 105 99 92
NPM1 15910 320 76 34
25 MN1 2466 990 800 720 1660 6792
NPM1 17600 120 80 31 60 6505
26 MN1 2566 62 71 34
NPM1 220 12 2 0
27 MN1 1890 63 61 12
NPM1 80279 12 1 1
28 MN1 1790 41 44 13
NPM1 2200 5 0 0
Resistant pt Target genes Diagnosis Post Induction
29 MN1 38910 25200
WT1 8450 9240
30 MN1 82100 72120
WT1 7220 6123
31 MN1 42193 63408
WT1 9920 13450
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Figure 3: Panel A and B: MN1 transcript expressed as number of copies/104 ABL copies (blue line) and CBFβ-MYH11 
transcript expressed as copy number/104 ABL copies (red line) at diagnosis and during follow-up in two patients with inv(16) 
who relapsed. MN1 increased above the upper normal limit three months before relapse in patient represented in panel A. Panel C: MN1 
transcript (blue line), CBFβ-MYH11transcript (red line) and WT1 transcript (pink line) at diagnosis and during follow-up of a patient with 
an inv(16) alteration who relapsed after two cycles of chemotherapy and allogeneic bone marrow transplantation (allo BMT). MN1 and 
WT1 increased above the upper normal limit four months before haematological relapse. PI= post induction, PC= post consolidation, CR= 
complete remission.
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MRD but it requires the presence of genetic markers in the 
leukemic clone including fusion transcripts or mutations 
[2, 3].
The disease monitoring became even more 
cumbersome with the genomic characterization of AML 
which elegantly demonstrated that, al least at onset, the 
acute leukemia is mainly constituted by a founding clone 
with a variable number of mutations and by additional 
subclones, nearly undetectable, carrying mutations 
different from the founding clone [4, 9].
These subclones might eventually be selected during 
chemotherapy and expand during the course of the disease 
[4, 9]. Considering the dynamic of the leukemic clones it 
should not be unpopular to suggest the use of a marker 
not specifically related to a clone but able to identify 
the presence of leukemic cells independently from their 
genetic lesions and their phenotype.
In addition, we must consider that in many 
laboratories NGS technology is not yet available and 
RQ-PCR targeting all the identified mutations is time 
consuming and expensive. The advantage of using a single 
“universal marker” with high sensitivity and specificity 
allow to better monitor the disease during therapy and in 
the remission phase.
Interestingly, the association of MN1 with 
myeloid malignancy goes beyond MN1 involvement 
in rare translocations such as t(12;22), as the gene is 
overexpressed in a significant percentage of AML patients. 
These has been already demonstrated in literature in 
some patients characterized by overexpression of the 
transcription factor ectropic viral integration 1 site (EVI1) 
[16] and in some adult AML patients without karyotypic 
abnormalities. In the latter case, overexpression of MN1 
was associated with a worse prognosis and shorter survival 
rate [14]. Despite the possibility that MN1 could represent 
an independent prognostic factor for AML patients, 
particularly for those with a normal karyotype, there 
are few data regarding the expression of MN1 in normal 
hematopoietic cells and in different subtypes of AML. 
Furthermore, there is currently no evidence that MN1 
could represent a suitable marker for minimal residual 
disease detection. Using a real time quantitative PCR 
approach, we show that MN1 expression is detectable in 
all normal bone marrow and peripheral blood samples 
and CD34 positive cells collected from healthy subjects, 
although we were able to estimate that normal subjects 
expressed very low MN1 levels. In contrast, a significant 
number of patients are characterized by high MN1 
transcript amount and, in several cases, the expression 
is at least 2 or 3 logs higher than controls. It appears 
that overexpression of MN1 is mainly associated with 
the inv16 chromosomal abnormality and with a normal 
karyotype, whereas in t(15;17) APL the values are 
consistently comparable to controls. In contrast, we were 
Figure 4: MN1 transcript (blue line) and WT1 transcript (pink line) expressed as number of copies/104 ABL copies at 
diagnosis and during follow-up of a patient with normal karyotype who obtained remission after chemotherapy and 
allogeneic bone marrow transplant and relapsed six months after transplant. In this patient, both markers, WT1 and MN1, 
returned to normal range and increased three months before relapse.
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unable to find any significant correlation between FLT3 
ITD or mutation or EVI-1 overexpression. Moreover, 
the finding that CD34-positive cells express low levels 
of MN1 transcript supports the notion that increased 
levels of MN1 expression are indeed specific of leukemic 
blasts and not a simple consequence of the degree of 
differentiation. Since a significant percentage of AML 
shows consistently increased MN1 expression levels, this 
could represent a candidate marker suitable to discriminate 
between normal and leukemic hematopoiesis and useful 
to establish the presence, persistence or reappearance of 
leukemic clone. In particular, our data show that 45% of 
AML cases lacking other molecular markers suitable for 
MRD monitoring express at diagnosis MN1 transcript 
values above the normal range established by healthy 
subjects. In this subset of patients, MN1 may represent 
a reliable marker for MRD detection. So far no data are 
available concerning the clinical significance of detection 
of MN1 expression by RT-PCR for monitoring patients 
with acute leukemia during follow-up. The data presented 
in this paper show that an accurate quantitative assessment 
of MN1 transcript amount allows to clearly distinguish 
between normal and abnormal expression levels of MN1 
and, as for WT1, can overcome the problem represented 
by the minimal amount of gene expression found in 
normal hematopoietic progenitors. The simultaneous 
quantitative assessment of the MN1 transcript and of the 
specific fusion gene or NPM1 mutation showed a good 
parallelism between the behaviour of the two markers. 
Indeed, minor discrepancies at low levels of expression 
of the two markers were observed. In particular, the 
decrease in MN1 expression seems to be particularly 
rapid compared to the fusion gene transcript during the 
induction of remission and its elevation before relapse 
is more rapid and therefore it is probably more sensitive 
in predicting relapse. Therefore, even though the degree 
of sensitivity for MRD detection by analysis of MN1 
expression remains to be established, the results obtained 
show that an increase in MN1 expression above normal 
levels can be of prognostic significance in predicting 
relapse during follow-up of AML patients. Although the 
MN1 gene requires validation as a marker for minimal 
residual disease in future prospective studies, it seems to 
be a promising marker for this purpose and further studies 
should be encouraged.
MATERIALS AND METHODS
After informed consent, 136 acute myeloid 
leukaemia patients and 50 healthy volunteers were 
included in the study. 136 bone marrow samples (BM) and 
36 paired peripheral blood samples (PB) were collected 
from 136 AML patients at diagnosis. In addition, 41 
patients were studied during follow-up. The median age 
was 48 years (range 18-74). All cases were classified 
according to FAB criteria, characterized at the cytogenetic 
level by conventional karyotyping and screened by 
RT-PCR for the presence of the most frequent fusion 
transcripts, as previously described.2 NPM1 mutations 3 
and FLT3 ITD or D835 mutations were screened. WT1 
quantitative assessment is available for all samples 
included in the study and, furthermore, in 40 out of 136 
BM samples EVI-1 quantitative assessment was also 
performed. The FAB distribution was as follows: FAB 
M0=21, FAB M1= 22, FAB M2=26, FAB M3= 25, FAB 
M4= 24, FAB M5=16, FAB M6=2. Patients younger 
than 60 years were treated following standard protocols 
established by the GIMEMA Cooperative Group for the 
treatment of adult patients with acute myeloid leukemia 
which included: Induction treatment with a 3-drug 
regimen: Daunorubicine (DNR) 50 mg/sqm/day on days 
1, 3 and 5; Cytosine-Arabinoside (ARA-C) 100 mg/sqm/
day on days 1 to 10; Etoposide 100 mg/sqm/day on days 
1 to 5; to be repeated in case of partial remission (PR). 
Consolidation therapy with DNR 50 mg/sqm/day on days 
4 to 6 and intermediate-doses ARA-C (500 mg/sqm/12 h 
on days 1 to 6) for patients achieving complete remission 
(CR) after either the first or the second induction cycle.
Additional consolidation treatments with high 
dose ARA-C were used followed, in high risk patients 
by allogeneic stem cell transplantation. (This regimen 
is indicated as treatment A in Table 2) Elderly or unfit 
patients were treated with two cycles of daunorubicin 45 
mg/sqm/day on days 1, 3 plus ARA-C 100 mg/sqm/day 
on days 1 to 7 followed, in same cases, by autologous 
stem cell transplantation. (This regimen is indicated as 
treatment B in Table 2)
Refractory or secondary AML were treated 
following the Mito-FLAG scheme (Fludarabine 30 mg/
sqm day 1-5, ARA-C 2000 mg/sqm day 1-5, mitoxantrone 
7 mg/sqm day 1,3,5 and G-CSF 5 μg/kg from day -1) 
and consolidated as described above. (This regimen 
is indicated as treatment C in Table 2). Finally Acute 
promyelocytic leukemia were treated with anthracycline-
based risk-adapted chemotherapy plus all-trans retinoic 
acid (ATRA) [17]. (This regimen is indicated as treatment 
D in Table 2)
Complete remission was defined according to 
standard criteria. Finally 30 PB and 20 BM and 6 CD34+ 
enriched peripheral blood stem cell samples collected 
from healthy volunteers were included as normal control.
Real time quantitative RT-PCR (RQ-PCR) 
analysis of MN1 and WT1
Total RNA was extracted using TRI Reagent 
solution (Ambion, Waltham, MA USA). Mononuclear 
cells were separated on a Ficoll–Hypaque density gradient. 
Total RNA was extracted by standard procedure. The RT 
(reverse transcription) step was performed as previously 
described [2, 8]. RQ-PCR reactions and fluorescence 
measurements were made on the ABI PRISM 7700 
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Sequence Detection System (PE Applied Byosystems, 
Foster City, USA).
Briefly, the RQ-PCR primers and probe for MN1 
detection were provided by ELItech, Turin, Italy
Primers and probe for MN1 detection are:
5’ AGAAGGCCAAACCCCAGAACC-3’
5’ GATGGTGAGGCCTTGTTTGCA-3’
5’ Fam-ACAGCAAAGAAGCCCAC-MGBNFQ 3’
For WT1 we followed the ELN standardized method 
reported [8].
The analysis was performed in triplicate and results 
showing a discrepancy >1 Ct in one of the wells were 
excluded and repeated. For quantitative assessment of 
MN1 a calibration curve with a plasmid containing MN1 
target sequences was used (ELItech, Turin, Italy). The 
MN1 values obtained by RQ-PCR were normalized with 
respect to the number of ABL transcripts and expressed as 
MN1 copy number every 104 copies of ABL. Quantitative 
assessment of CBF-MYH11 and RUNX1-AML1 transcripts 
was determined using primers and probes according to 
standardized procedures.2
Real time quantitative RT-PCR (RQ-PCR) 
analysis of EVI-1
For EVI-1 and ABL quantification, specific assays 
on demand kits of primers and probe (assay ID for EVI-1 
HS01118675_m1 and for ABL Hs00245445_m1 (Applied 
Byosystems, Foster City, USA) were used following the 
manufacturer’s instructions.
All sample analysis was performed in triplicate and 
results showing a discrepancy >1 Ct in one of the wells 
were excluded and repeated.
EVI-1 Ct obtained by RQ-PCR was normalized with 
respect to the Ct of ABL and calibrated with universal 
RNA (Stratagene, Santa Clara, California, USA) and 
finally expressed as 2-∆∆Ct.
CD34-positive cells enrichment
CD34+ cells were enriched according to a magnetic 
cell sorting methodology (MACS; Miltenyi Biotec, 
Bergisch Gladbach, Germany).Briefly, mononuclear 
cells were labeled with a haptenized CD34 antibody 
(QBEND\10) that was magnetically labelled in a second 
step reaction with an anti-hapten antibody coupled 
to super paramagnetic microbeads. Labelled cells 
were then separated using a high gradient magnetic 
separator column placed in a strong magnetic field. The 
magnetically stained cells were retained in the column, 
and when the latter was removed from the magnetic 
field, CD34-positive cells were eluted. At the end of 
the procedure, CD34 positive cells represented more 
that 90% of the total as determined by flow cytometric 
analysis.
Statistical analysis
MN1 values obtained for different types of leukemia 
were compared using the Student’s t-test.
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